NO337010B1 - Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den - Google Patents
Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den Download PDFInfo
- Publication number
- NO337010B1 NO337010B1 NO20063516A NO20063516A NO337010B1 NO 337010 B1 NO337010 B1 NO 337010B1 NO 20063516 A NO20063516 A NO 20063516A NO 20063516 A NO20063516 A NO 20063516A NO 337010 B1 NO337010 B1 NO 337010B1
- Authority
- NO
- Norway
- Prior art keywords
- agomelatine
- crystalline form
- form iii
- disorders
- pharmaceutical compositions
- Prior art date
Links
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims description 17
- 229960002629 agomelatine Drugs 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 4
- 238000010586 diagram Methods 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 230000007170 pathology Effects 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000027559 Appetite disease Diseases 0.000 claims description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001193 melatoninergic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Krystallinsk form III av forbindelsen med formel (l): karakterisert ved dens pulverrøntgendiffraksjonsdiagram. Medikamenter.
Description
Foreliggende oppfinnelse vedrører en ny krystallinsk form III av agomelatin, eller /V-[2-(7-metoksy-l-naftyl)etyl]acetamid, med formel (I):
en fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inne-holdende den.
Agomelatin, eller/V-[2-(7-metoksy-l-naftyl)etyl]acetamid, har verdifulle farmako-logiske egenskaper.
Riktignok har den den dobbelt karakteristiske egenskap å være, på den ene side, en agonist av melatoninergiske systemreseptorer og, på den andre side, en anta-gonist av 5-HT2c-reseptoren. Disse egenskaper gir aktivitet i sentralnervesystemet og, mer spesielt, i behandlingen av alvorlig depresjon, vinterdepresjoner, søvn-forstyrrelser, kardiovaskulære patologier, patologier i fordøyelsessystemet, insomni og tretthet som skyldes jetlag, appetittforstyrrelser og obesitet.
Agomelatin, dens fremstilling og dens terapeutiske anvendelse har blitt beskrevet i europeisk patentbeskrivelse EP 0 447 285.
I betraktning av denne forbindelsens farmasøytiske verdi, har det blitt viktig å være i stand til å oppnå dem med utmerket renhet, med veldefinert krystallinsk form, fullstendig reproduserbart, hvilket som et resultat foreviser verdifulle karakteristiske egenskaper hva gjelder formulering og tilstrekkelig stabilitet til å tillate dens lagring for lange perioder uten spesielle behov for temperatur, lys, fuktighet eller oksygennivå.
Patentbeskrivelse EP 0 447 285 beskriver fremstillingen av agomelatin i åtte trinn, startende fra 7-metoksy-l-tetralon. Imidlertid spesifiserer ikke dette dokument betingelsene for å oppnå agomelatin i en form som foreviser de karakteristiske egenskaper på en reproduserbar måte.
Søkeren har nå utviklet en ny synteseprosess som tillater agomelatin å bli oppnådd i en veldefinert, fullstendig reproduserbar krystallinsk form som spesielt fremviser verdifulle karakteristiske egenskaper for formulering.
Mer spesielt vedrører den foreliggende oppfinnelse den krystallinsk form III av forbindelsen med formel (I), kjennetegnet ved det følgende pulverrøntgen-diffraksjonsdiagram, målt ved å anvende et Siemens D5005-diffraktometer (kobber antikatode) og uttrykket i form av interplanær avstand d, Braggs vinkel 2 theta, intensitet og relativ intensitet (uttrykket som en prosent av den mest intense stråle):
Oppfinnelsen vedrører også en fremgangsmåte for fremstillingen av den krystallinske form III av forbindelsen med formel (I), hvilken fremgangsmåte erkarakterisertved at agomelatin varmes ved 110 °C inntil smeltingen er fullstendig, og deretter langsomt avkjøles inntil krystallisasjon.
En fordel ved å oppnå denne krystallinske form er at den tillater fremstillingen av farmasøytiske formuleringer som har en konsistent og reproduserbar sammensetning, hvilket er spesielt fordelaktig når formuleringene skal anvendes for oral administrasjon.
En farmakologisk studie av den således oppnådde formen III har demonstrert at den har betydelig aktivitet med hensyn på sentralnervesystemet og med hensyn på mikrosirkulasjon, som gjør det mulig å konstatere at den krystallinske form III av agomelatin er nyttig i behandlingen av stress, søvnforstyrrelser, angst, alvorlig depresjon, vinterdepresjoner, kardiovaskulære patologier, patologier i fordøyelses-systemet, insomni og tretthet på grunn av jetlag, schizofreni, panikkanfall, melankoli, appetittforstyrrelser, obesitet, insomni, smerte, psykotiske lidelser, epilepsi, diabetes, Parkinsons sykdom, senil demens, forskjellige lidelser assosiert med normal eller patologisk aldring, migrene, hukommelsestap, Alzheimers sykdom og i cerebrale sirkulasjonsforstyrrelser. I et annet aktivitetsfelt viser det seg at den krystallinske III-form av agomelatin kan anvendes i behandlingen av seksuell dys-funksjon, at den har ovulasjonshemmende og immunmodulerende egenskaper og at den passer for anvendelse i behandlingen av cancere.
Den krystallinske form III av agomelatin vil fortrinnsvis anvendes i behandlingen av alvorlig depresjon, vinterdepresjoner, søvnforstyrrelser, kardiovaskulære patologier, insomni og tretthet på grunn av jetlag, appetittforstyrrelser og obesitet.
Oppfinnelsen vedrører også farmasøytiske sammensetninger omfattende som aktiv ingrediens den krystallinske form III av agomelatin sammen med én eller flere pas-sende inerte, ikke-toksiske eksipienser. Blant de farmasøytiske sammensetninger ifølge oppfinnelsen kan det nevnes, mer spesielt, de som er egnet for oral, parente-ral (intravenøs eller subkutan) eller nasal administrasjon, tabletter eller drageer, granuler, sublingvale tabletter, gelatinkapsler, lozengere, suppositorier, kremer, salver, dermale geler, injiserbare preparater, drikkbare suspensjoner og desin-tegrerbare pastaer.
Den nyttige dosering kan tilpasses i henhold til lidelsens natur og alvorlighet, admi-nistrasjonsruten og pasientens alder og vekt. Doseringen varierer fra 0,1 mg til 1 g per dag i én eller flere administrasjoner.
Eksemplene under illustrerer oppfinnelsen, men begrenser den ikke på noen måte.
Eksempel 1: Krystallinsk form III av /V-[2-(7-metoksy-l-naftyl)etyl]acetamid
100 g /V-[2-(7-metoksy-l-naftyl)etyl]acetamid varmes ved 110 °C i en ventilert inkubator inntil smeltingen er fullstendig, og avkjøles deretter langsomt inntil krystallisasjon. Den oppnådde krystallinsk form III erkarakterisert veddet følgende pulverrøntgendiffraksjonsdiagram, målt ved å anvende et Siemens D5005-diffraktometer (kobber antikatode) og uttrykket i form av interplanær avstand d, Braggs vinkel 2 theta, intensitet og relative intensitet (uttrykket som en prosent av den mest intense stråle):
Eksempel 2: Farmasøytisk sammensetning
Eksempel 3: Farmasøytisk sammensetning
Claims (4)
1. Krystallinsk form III av agomelatin med formel (I):
karakterisert veddet følgende pulverrøntgendiffraksjonsdiagram, målt ved å anvende et diffraktometer (kobber antikatode) og uttrykket i form av interplanær avstand d, Braggs vinkel 2 theta, intensitet og relativ intensitet (uttrykket som en prosent med hensyn på den mest intense stråle):
2. Fremgangsmåte for fremstillingen av den krystallinske form III av forbindelsen med formel (I) ifølge krav 1,
karakterisert vedat agomelatin varmes ved 110 °C inntil smeltingen er fullstendig, og deretter langsomt avkjøles inntil krystallisasjon.
3. Farmasøytiske sammensetninger omfattende som aktiv ingrediens krystallinsk form III av agomelatin ifølge krav 1, i kombinasjon med én eller flere farmasøy-tisk akseptable, inerte, ikke-toksiske bærere.
4. Farmasøytiske sammensetninger ifølge krav 3 for anvendelse i fremstillingen av et medikament for behandlingen av søvnforstyrrelser, stress, angst, vinterdepresjoner eller alvorlig depresjon, kardiovaskulære patologier, patologier i for-døyelsessystemet, insomni og tretthet på grunn av jetlag, schizofreni, panikkanfall, melankoli, appetittforstyrrelser, obesitet, insomni, psykotiske forstyrrelser, epilepsi, diabetes, Parkinsons sykdom, senil demens, forskjellige forstyrrelser assosiert med normal eller patologisk aldring, migrene, hukommelsestap, Alzheimers sykdom, cerebrale sirkulasjonsforstyrrelser, og også i seksuell dys-funksjon, som ovulasjonsinhibitorer, immunmodulatorer og cancere.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508276A FR2889521B1 (fr) | 2005-08-03 | 2005-08-03 | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20063516L NO20063516L (no) | 2007-02-05 |
| NO337010B1 true NO337010B1 (no) | 2015-12-21 |
Family
ID=36587257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063516A NO337010B1 (no) | 2005-08-03 | 2006-08-02 | Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den |
Country Status (36)
| Country | Link |
|---|---|
| EP (3) | EP2008993A1 (no) |
| JP (1) | JP4580370B2 (no) |
| CN (1) | CN100450995C (no) |
| AR (1) | AR057713A1 (no) |
| AU (1) | AU2006203336B2 (no) |
| BR (1) | BRPI0603074A (no) |
| CA (1) | CA2555117A1 (no) |
| CY (1) | CY1118637T1 (no) |
| DK (1) | DK2210872T3 (no) |
| EA (1) | EA011031B1 (no) |
| ES (1) | ES2614934T3 (no) |
| FR (1) | FR2889521B1 (no) |
| GE (1) | GEP20094576B (no) |
| GT (1) | GT200600347A (no) |
| HK (1) | HK1098130A1 (no) |
| HR (1) | HRP20170095T1 (no) |
| HU (1) | HUE030506T2 (no) |
| JO (1) | JO3360B1 (no) |
| LT (1) | LT2210872T (no) |
| MA (1) | MA28449B1 (no) |
| ME (1) | ME02689B (no) |
| MX (1) | MXPA06008790A (no) |
| MY (1) | MY142856A (no) |
| NO (1) | NO337010B1 (no) |
| NZ (1) | NZ548862A (no) |
| PE (1) | PE20070213A1 (no) |
| PL (1) | PL2210872T3 (no) |
| PT (1) | PT2210872T (no) |
| RS (1) | RS55499B1 (no) |
| SA (1) | SA06270253B1 (no) |
| SG (1) | SG130112A1 (no) |
| SI (1) | SI2210872T1 (no) |
| TW (1) | TWI389873B (no) |
| UA (1) | UA83719C2 (no) |
| WO (1) | WO2007015003A2 (no) |
| ZA (1) | ZA200606454B (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2934856B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
| CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
| WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
| CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
| CN102050755B (zh) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | 阿戈美拉汀的晶型及其制备方法 |
| CN101709036B (zh) * | 2009-12-17 | 2012-07-04 | 天津药物研究院 | 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备 |
| CN101781226B (zh) * | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
| CN101774937B (zh) * | 2010-02-05 | 2014-01-08 | 天津市汉康医药生物技术有限公司 | N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺及其组合物 |
| EP2580183B1 (en) | 2010-06-10 | 2014-07-23 | Gador S.A. | New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide |
| CZ303787B6 (cs) * | 2011-01-21 | 2013-05-02 | Zentiva, K.S. | Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice |
| CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
| CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| WO2013082302A1 (en) | 2011-11-30 | 2013-06-06 | Ratiopharm Gmbh | Agomelatine-urea complex and crystalline forms thereof |
| CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
| WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
| FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| PL2810656T3 (pl) | 2013-06-06 | 2018-01-31 | Zentiva Ks | Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów |
| CZ2013621A3 (cs) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci |
| WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
| EP3075724B1 (en) | 2015-03-31 | 2023-07-12 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR2866336B1 (fr) * | 2004-02-13 | 2006-03-24 | Servier Lab | Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine |
-
2005
- 2005-08-03 FR FR0508276A patent/FR2889521B1/fr not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000866A patent/PE20070213A1/es not_active Application Discontinuation
- 2006-07-24 JO JOP/2006/0245A patent/JO3360B1/ar active
- 2006-07-24 MA MA29210A patent/MA28449B1/fr unknown
- 2006-07-31 GT GT200600347A patent/GT200600347A/es unknown
- 2006-08-01 NZ NZ548862A patent/NZ548862A/en not_active IP Right Cessation
- 2006-08-01 SA SA06270253A patent/SA06270253B1/ar unknown
- 2006-08-01 SG SG200605175-9A patent/SG130112A1/en unknown
- 2006-08-02 WO PCT/FR2006/001868 patent/WO2007015003A2/fr active Application Filing
- 2006-08-02 ME MEP-2017-33A patent/ME02689B/me unknown
- 2006-08-02 MY MYPI20063735A patent/MY142856A/en unknown
- 2006-08-02 LT LTEP10003436.2T patent/LT2210872T/lt unknown
- 2006-08-02 RS RS20161179A patent/RS55499B1/sr unknown
- 2006-08-02 DK DK10003436.2T patent/DK2210872T3/en active
- 2006-08-02 EP EP08017458A patent/EP2008993A1/fr not_active Withdrawn
- 2006-08-02 GE GEAP20069558A patent/GEP20094576B/en unknown
- 2006-08-02 HU HUE10003436A patent/HUE030506T2/en unknown
- 2006-08-02 SI SI200632141A patent/SI2210872T1/sl unknown
- 2006-08-02 PT PT100034362T patent/PT2210872T/pt unknown
- 2006-08-02 TW TW095128299A patent/TWI389873B/zh not_active IP Right Cessation
- 2006-08-02 EP EP10003436.2A patent/EP2210872B1/fr active Active
- 2006-08-02 EP EP06291253A patent/EP1752445A1/fr not_active Withdrawn
- 2006-08-02 NO NO20063516A patent/NO337010B1/no not_active IP Right Cessation
- 2006-08-02 EA EA200601274A patent/EA011031B1/ru not_active IP Right Cessation
- 2006-08-02 UA UAA200608688A patent/UA83719C2/ru unknown
- 2006-08-02 ES ES10003436.2T patent/ES2614934T3/es active Active
- 2006-08-02 PL PL10003436T patent/PL2210872T3/pl unknown
- 2006-08-02 AR ARP060103364A patent/AR057713A1/es not_active Application Discontinuation
- 2006-08-03 ZA ZA200606454A patent/ZA200606454B/xx unknown
- 2006-08-03 JP JP2006211620A patent/JP4580370B2/ja not_active Expired - Fee Related
- 2006-08-03 CA CA002555117A patent/CA2555117A1/fr not_active Abandoned
- 2006-08-03 MX MXPA06008790A patent/MXPA06008790A/es active IP Right Grant
- 2006-08-03 BR BRPI0603074-2A patent/BRPI0603074A/pt not_active Application Discontinuation
- 2006-08-03 CN CNB2006101083967A patent/CN100450995C/zh not_active Expired - Fee Related
- 2006-08-03 AU AU2006203336A patent/AU2006203336B2/en not_active Ceased
-
2007
- 2007-04-30 HK HK07104585.6A patent/HK1098130A1/xx not_active IP Right Cessation
-
2017
- 2017-01-20 HR HRP20170095TT patent/HRP20170095T1/hr unknown
- 2017-02-10 CY CY20171100190T patent/CY1118637T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO337010B1 (no) | Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den | |
| NO336967B1 (no) | Ny krystallinsk form v av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den | |
| DK2058296T3 (en) | New crystal form vi of agomelatine, process for its preparation, and pharmaceutical compositions containing it | |
| AU2006203340B2 (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7358395B2 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7939566B2 (en) | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7910625B2 (en) | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| KR100904116B1 (ko) | 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물 | |
| KR20070017020A (ko) | 아고멜라틴의 결정질 형태 ⅳ, 이의 제조 방법 및 이를함유하는 약제 조성물 | |
| KR20070017019A (ko) | 아고멜라틴의 결정질 형태 ⅲ, 이의 제조 방법 및 이를함유하는 약제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |